The following Terms and Conditions (‘Terms’) apply to your participation in the MyeCare Program sponsored by GlaxoSmithKline Australia Pty Ltd (GSK) and managed by Partizan Worldwide Pty Ltd (Partizan) (‘us’, ‘we’ or ‘our’).
Please read these Terms and the MyeCare Program Privacy Policy. It is your right to refuse to agree to the terms and conditions outlined here; however, if you do not agree, you may not be able to participate in the MyeCare Program. If you have any questions or require additional information, please speak to your doctor, or contact the MyeCare Program Team on 1800 140 272.
Your enrolment and use of the MyeCare Program shall constitute acceptance of the following terms and conditions:
You may only access and use the MyeCare Program in accordance with these Terms and other instructions that we may provide you with.
You understand and acknowledge that involvement in the MyeCare Program is designed to complement and support the prescribing instructions of your Healthcare Professional and does not replace your usual medical care. That is, the MyeCare Program does not perform, nor should it be relied upon for, (a) medical diagnosis; (b) treatment; (c) provision of medical advice; or (d) calculating or assessing the appropriate dosages of GSK products. These responsibilities remain with your treating Healthcare Professional. You must contact your Healthcare Professional for any queries regarding your treatment or condition.
You confirm that you are eligible to participate in the MyeCare Program on the basis that you are being prescribed a GSK product associated with the MyeCare Program. If you are unsure, please contact your Healthcare Professional for further information. If you are unable to be the primary contact and wish to nominate an alternative, carer consent must be provided.
We reserve the right to exclude patients who are not eligible to use the MyeCare Program.
By enrolling in the MyeCare Program, you also consent to the MyeCare Program team and authorised Specsavers or other eye care professional staff corresponding with members of your healthcare team (including your prescribing Healthcare Professional) to provide them with information relevant to your healthcare management and progress.
By participating in the MyeCare Program, you consent to the MyeCare team corresponding with you (by phone, email, SMS, websites, digital applications or mail), to provide you with information relevant to your status and/or the support services that we will provide to you.
You give permission for the MyeCare team, GSK, or a third party acting on its behalf, to contact your Healthcare Professional should you experience an adverse event involving a GSK product.
If applicable, you give permission for a MyeCare Program team member to contact your nominated medical clinic, community pharmacy and/or hospital pharmacy to discuss the ongoing administration of your prescribed GSK product with your doctor, practice nurse or pharmacist.
By continuing in the MyeCare Program, you understand and agree that adverse events you experience involving GSK products will be collected by the MyeCare team and that they may contact you for further information relating to these adverse events, if required.
Services provided under the MyeCare Program may vary depending on:
Patient services provided under the MyeCare Program may include any of the following:
Patient enrolment into the MyeCare Program occurs by using a web-based enrolment form provided by email after your Healthcare Professional has discussed the MyeCare Program, gained your consent and provided an electronic referral at myecare.com.au;
Upon receipt of your enrolment request, the MyeCare Program team will verify your eligibility before your enrolment can be accepted.
By providing your personal information and/or participating in the MyeCare Program, you consent to Partizan collecting, using, storing, transferring and disclosing your personal information, including your sensitive information, in accordance with these Terms and the MyeCare Program Privacy Notice. This includes your name, age, contact details; as well as your sensitive information relating to the GSK product you are prescribed or your medical condition.
Partizan uses your personal information, including your sensitive information, to manage your participation in the MyeCare Program. Partizan will not use your personal information for any other purposes unless we have your consent to do so, or we are required to do so by law. If you do not provide personal information when requested, Partizan may not be able to manage your participation in the MyeCare Program and, as a result, you may not be able to participate.
Partizan may collect and share personal information directly from you, and from your prescribing Healthcare Professional. Partizan may use your personal information to contact you as necessary to clarify certain aspects of your personal information and/or to review your experience regarding treatment of your condition(s) and participation in the MyeCare Program. Partizan may also disclose your personal information to other persons involved with the MyeCare Program, such as third party service providers, in accordance with the MyeCare Program Privacy Policy (e.g. mailhouse suppliers responsible for posting out MyeCare Program materials).
This Program may be terminated at any time at the direction of the Sponsor, for regulatory or safety reasons or any other reason the Sponsor deems necessary.
Your personal information will be stored securely in a Program database in accordance with these Terms and the MyeCare Program Privacy Policy. Partizan takes reasonable steps to protect such personal information from misuse, interference, loss and unauthorised access, modification or disclosure in accordance with the privacy laws of Australia, as applicable.
Your personal information will be handled in accordance with the MyeCare Program Privacy Policy which details (amongst other things) how you can access, correct or complain about the handling of your personal information, and how Partizan will respond to your requests or complaints. If you have any questions or if you would like a copy of the MyeCare Program Privacy Policy, or if you would like to see, correct or delete your records or if you have any queries or complaints, please contact the MyeCare Program at any time by calling 1800 140 272 or writing to the MyeCare Program at support@myecare.com.au.
DATA SHARING WITH GSK: Although your information will be treated in confidence, should Partizan be made aware of an adverse event, we will need to provide this to GSK, who may be required to report this to the relevant regulatory authorities, even if it has already been reported by you directly to a doctor, pharmaceutical company or regulatory authority. You acknowledge that your personal or sensitive information may be disclosed to GSK if you have given your permission to such disclosure and that GSK may disclose your personal or sensitive information to the relevant regulatory authorities solely for the purpose of, and to the extent required to, report such adverse event. De-identified amalgamated information relating to your participation in the MyeCare Program will be collated into a report for GSK. GSK may use this information for analysis and may publish it in reports or medical publications. You will not be able to be identified in any form of report or publication. Any personal information collected by Partizan that is shared with GSK will be handled in accordance with GSK’s Privacy Policy.
You have the right to opt out of the MyeCare Program at any time by calling the MyeCare Program on 1800 140 272 or writing to the MyeCare Program at support@myecare.com.au.
We may also suspend or cancel your access to the MyeCare Program at any time without advance notice and for any reason, although we will use reasonable efforts to provide you with notice wherever practicable.
We reserve our right to modify these Terms at any time, including MyeCare Program eligibility requirements. We will use reasonable endeavours to ensure that you are alerted to changes, such as contacting you via email. Your subsequent continued participation in the MyeCare Program after such changes have been made will constitute acceptance of the new Terms.
We may also update, improve or otherwise modify the software and the MyeCare Program from time to time. If that happens, you may need to download or install updates of the software in order to continue using the MyeCare Program.
If you have any questions about the MyeCare Program or these Terms, please contact the MyeCare Program team by phone on 1800 140 272 or by email at support@myecare.com.au
You are receiving this communication because you have enrolled in the MyeCare Program. For more information about your treatment and medical advice, please consult your Healthcare Professional.
This material is intended for patients who have been prescribed belantamab mafodotin. It does not contain all available information and is not a substitute for medical advice.
This material is provided in response to a Healthcare Professional’s request for compassionate supply of belantamab mafodotin. Belantamab mafodotin is not currently approved for use in Australia by the Therapeutic Goods Administration (TGA).
Trade marks are owned by or licensed to the GSK group of companies. © 2025 GSK group of companies or its licensor. GlaxoSmithKline Australia Pty Ltd, Melbourne, VIC. NX-AU-MMU-PSP-250003. Date of approval: September 2025.
The MyeCare Program has been developed and supported by GlaxoSmithKline Australia Pty Ltd, and is managed by Partizan Worldwide Pty Ltd (an independent provider of patient support services). Partizan Worldwide Pty Ltd, Level 8/321 Kent Street, Sydney, NSW 2000. ABN: 18 115 985 825. For questions about the MyeCare Program, contact the team on 1800 140 272 or email support@myecare.com.au.